Calcium channel blockers (versus unexposed)

Caesarean

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17161
R71972		 Vaclavik - Amlodipine, 2024 Caesarean section during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 2.82 [2.35;3.38] -/221   -/252,856 - 221
ref
S13875
R54260		 Darcie - Isradipine, 2004 Cesarean late pregnancy prospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 1.91 [0.54;6.78] C 28/39   8/14 36 39
ref
S13988
R54963		 Magee - Calcium blockers, 1996 Cesarean section at least 1st trimester excluded prospective cohort unexposed (general population or NOS) Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched 1.51 [0.69;3.28] C
excluded (exposition period) 		18/47   21/72 39 47
ref
S13986
R54916		 Wide-Swensson - Isradipine, 1995 Cesarean section 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified 1.31 [0.52;3.30] C 14/47   11/45 25 47
ref
Total 3 studies 2.35 [1.51;3.68] 61 307
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Vaclavik - Amlodipine, 2024Vaclavik - Amlodipine, 2024 2.82[2.35; 3.38]-22171%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: unclear Darcie - Isradipine, 2004Darcie - Isradipine, 2004 1.91[0.54; 6.78]363911%ROB confusion: seriousROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Wide-Swensson - Isradipine, 1995Wide-Swensson - Isradipine, 1995 1.31[0.52; 3.30]254718%ROB confusion: lowROB selection: lowROB classification: moderateROB missing: lowROB mesure: lowROB reporting: moderate Total (3 studies) I2 = 30% 2.35[1.51; 3.68]613070.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.80[2.34; 3.35]362600%NAVaclavik - Amlodipine, 2024 Darcie - Isradipine, 2004 2 case control studiescase control studies 0 RCTRCT 1.31[0.52; 3.30]2547 -NAWide-Swensson - Isradipine, 1995 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.82[2.35; 3.38]-221 -NAVaclavik - Amlodipine, 2024 1 unexposed, sickunexposed, sick 1.49[0.71; 3.15]61860%NADarcie - Isradipine, 2004 Wide-Swensson - Isradipine, 1995 2 Tags Adjustment   - No  - No 2.80[2.34; 3.35]362600%NAVaclavik - Amlodipine, 2024 Darcie - Isradipine, 2004 2   - Randomisation  - Randomisation 1.31[0.52; 3.30]2547 -NAWide-Swensson - Isradipine, 1995 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 2.35[1.51; 3.68]6130730%NAVaclavik - Amlodipine, 2024 Darcie - Isradipine, 2004 Wide-Swensson - Isradipine, 1995 3 All studiesAll studies 2.35[1.51; 3.68]6130730%NAVaclavik - Amlodipine, 2024 Darcie - Isradipine, 2004 Wide-Swensson - Isradipine, 1995 30.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.82[2.35; 3.38]-221 -NAVaclavik - Amlodipine, 2024 1 unexposed, sick controlsunexposed, sick controls 1.49[0.71; 3.15]61860%NADarcie - Isradipine, 2004 Wide-Swensson - Isradipine, 1995 20.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Alavifard (Nifedipine) (Caesarean delivery (v ...Alavifard (Nifedipine) (Caesarean delivery (versus Hydralazine)) 1.02[0.48; 2.04]-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Alavifard (Nifedipine) (Caesarean delivery (v ...Alavifard (Nifedipine) (Caesarean delivery (versus Labetalol)) 1.06[0.47; 2.22]-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION (Caesarean section) 1.02[0.77; 1.33]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT4 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION (DUPLICATE) (Caesarean section) 1.02[0.77; 1.33]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT4 Abalos (Caesarean section (RCT versus no anti ...Abalos (Caesarean section (RCT versus no antihypertensive drugs/placebo)) 0.94[0.79; 1.11]37%-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT3 Firoz (Nifedipine) (Caesarean section (versus ...Firoz (Nifedipine) (Caesarean section (versus hydralazine iv)) 0.85[0.56; 1.29]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Firoz (Nifedipine) (Caesarean section (versus ...Firoz (Nifedipine) (Caesarean section (versus Labetalol iv)) 1.23[0.76; 1.98]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Bellos - Amlodipine (Cesarean delivery (Rando ...Bellos - Amlodipine (Cesarean delivery (Randomized controlled trial and Cohort studies)) 1.35[0.38; 4.80]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bellos - Nifedipine (Cesarean delivery (Rando ...Bellos - Nifedipine (Cesarean delivery (Randomized controlled trial and Cohort studies)) 0.85[0.56; 1.29]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bellos - Amlodipine (Cesarean delivery (Rando ...Bellos - Amlodipine (Cesarean delivery (Randomized controlled trial only)) 1.35[0.38; 4.80]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bellos - Nifedipine (Cesarean delivery (Rando ...Bellos - Nifedipine (Cesarean delivery (Randomized controlled trial only)) 0.85[0.56; 1.29]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 2.35[1.51; 3.68]30%307----Vaclavik - Amlodipine, 2024 Darcie - Isradipine, 2004 Wide-Swensson - Isradipine, 1995 30.510.01.0